From: OncLive <edigest@onclive.com>

Sent: <Day, Month xx, 2020>
To: <<Email Address>>

Subject: Live Broadcast Registration Confirmation: A New First-Line Combination

for Advanced Renal Cell Carcinoma

No Images? Click here

Dear [Full Name],

We are pleased to confirm your registration to view this live broadcast to gain an expert perspective on the changing therapeutic landscape and learn about a new first-line combination approach for patients with advanced renal cell carcinoma.

Thank you for your participation!

Date: [Month/Day/20]

Time: [XX:XXpm]

VIEW LIVE BROADCAST

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.

Join Our RCC Experts:



Daniel James George, MD

Professor of Medicine and Surgery

Director of GU Oncology

Co-Leader, DCI Center for Prostate & Urologic Cancers

Duke University Medical Center



Ulka Vaishampayan, MD
Professor of Medicine
Division of Hematology/Oncology
University of Michigan



Sumanta Kumar Pal, MD
Clinical Professor
Department of Medical Oncology & Experimental
Therapeutics
City of Hope

In this Live Broadcast Dr. George, Dr. Vaishampayan, and Dr. Pal will:



Explore key efficacy and safety data for a new first-line combination regimen



Provide expert perspectives on clinical trial data



Share clinical insights through a live Q&A

VIEW LIVE BROADCAST






CA-1716 01/21

credit.

This program is not certified for Continuing Medical Education

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.





From: OncLive <edigest@onclive.com>

Sent: <Day, Month xx, 2020>
To: <<Email Address>>

Subject: Live Broadcast Registration Confirmation: A New

First-Line Combination for Advanced Renal Cell Carcinoma

No Images? Click here

Dear [Full Name],

We are pleased to confirm your registration to view this live broadcast to gain an expert perspective on the changing therapeutic landscape and learn about a new first-line combination approach for patients with advanced renal cell carcinoma.

Thank you for your participation!

Time: [XX:XXpm]

Date: [Month/Day/20]

VIEW LIVE BROADCAST

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.

Join Our RCC Experts:



Daniel James George, MD

Professor of Medicine and Surgery
Director of GU Oncology
Co-Leader, DCI Center for Prostate & Urologic Cancers
Duke University Medical Center



Division of Hematology/Oncology

University of Michigan



Therapeutics

City of Hope

In this Live Broadcast Dr. George, Dr.

Vaishampayan, and Dr. Pal will:

first-line combination regimen



data

Provide expert perspectives on clinical trial

Explore key efficacy and safety data for a new



Share clinical insights through a live Q&A

EW LIVE BROADCAST

OncLive



CA-1716 01/21
This program is not certified for Continuing Medical Education credit.

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests

2 Clarke Dr I Suite 100 | Cranbury, NJ | 08512

or spouses.

OncLive® – an MJH Life Sciences™ brand Copyright 2021 © Intellisphere, LLC

Preferences I Unsubscribe

